The investigation was conducted on client‐owned moderately arthritic dogs with two objectives: (i) to evaluate therapeutic efficacy of type‐II collagen (UC‐II) alone or in combination with ...glucosamine hydrochloride (GLU) and chondroitin sulphate (CHO), and (ii) to determine their tolerability and safety. Dogs in four groups (n = 7–10), were treated daily for a period of 150 days with placebo (Group‐I), 10 mg active UC‐II (Group‐II), 2000 mg GLU + 1600 mg CHO (Group‐III), and UC‐II + GLU + CHO (Group‐IV). On a monthly basis, dogs were evaluated for observational pain (overall pain, pain upon limb manipulation, and pain after physical exertion) using different numeric scales. Pain level was also measured objectively using piezoelectric sensor‐based GFP for peak vertical force and impulse area. Dogs were also examined every month for physical, hepatic (ALP, ALT and bilirubin) and renal (BUN and creatinine) functions. Based on observations, significant (p < 0.05) reduction in pain was noted in Group‐II, III, and IV dogs. Using GFP, significant increases in peak vertical force (N/kg body wt) and impulse area (N s/kg body wt), indicative of a decrease in arthritis associated pain, were observed in Group‐II dogs only. None of the dogs in any group showed changes in physical, hepatic or renal functions. In conclusion, based on GFP data, moderately arthritic dogs treated with UC‐II (10 mg) showed a marked reduction in arthritic pain with maximum improvement by day 150. UC‐II, GLU and CHO operate through different mechanisms of action, and were well tolerated over a period of 150 days.
